Kenneth C. Anderson, MD

Kenneth C. Anderson, MD, discusses the recent FDA ODAC decision regarding the use of cilta-cel in relapsed/refractory multiple myeloma.

Kenneth C. Anderson, MD, a 2014 Giant of Cancer Care in Myeloma, program director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, institute physician, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, discusses how currently available agents will continue to impact the field of multiple myeloma.

Kenneth C. Anderson, MD, Giant of Cancer Care: Myeloma, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, discusses how the definition of myeloma has changed.